Alemtuzumab 12 mg in 1.2 mL Injection
RxNorm 1594658
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1594658 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: alemtuzumab 12 mg in 1.2 mL Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
1.2 mL alemtuzumab 10 mg/ML Injection
(Atom ID: 7250313)
PSNPrescribable
Prescribable Name (PSN):
Alemtuzumab 12 mg in 1.2 mL Injection
(Atom ID: 7250355)
SYPrescribable
Synonym (SY):
Alemtuzumab 12 mg per 1.2 mL Injection
(Atom ID: 7250356)
Patient Education
Alemtuzumab Injection (Chronic Lymphocytic Leukemia)
Alemtuzumab injection is used to treat B-cell chronic lymphocytic leukemia (B-CLL; a slowly developing cancer in which too many of a certain type of white blood cell accumulate in the body). Alemtuzumab is in a class of medications called monoclonal antibodies. It works by activating the immune system to destroy cancer cells. Alemtuzumab is also available as an injection (Lemtrada) that is used to treat multiple sclerosis (a disease in which the nerves do not function properly; you may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control). This monograph only gives information about alemtuzumab injection (Campath) for B-CLL. If you are receiving alemtuzumab for multiple sclerosis, read the monograph entitled Alemtuzumab Injection (Multiple Sclerosis).
[Learn More]
Alemtuzumab Injection (Multiple Sclerosis)
Alemtuzumab injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) who have not improved with at least two or more MS medications including: relapsing-remitting forms (course of disease where symptoms flare up from time to time) or secondary progressive forms (course of disease where relapses occur more often). Alemtuzumab is in a class of medications called monoclonal antibodies. It works by decreasing the action of immune cells that may cause nerve damage. Alemtuzumab is also available as an injection (Campath) that is used to treat chronic lymphocytic leukemia (a slowly developing cancer in which too many of a certain type of white blood cell accumulates in the body). This monograph only gives information about alemtuzumab injection (Lemtrada) for multiple sclerosis. If you are receiving alemtuzumab for chronic lymphocytic leukemia, read the monograph entitled Alemtuzumab Injection (Chronic Lymphocytic Leukemia).
[Learn More]
* Please review the disclaimer below.
